Shots:

• Kyverna get the rights to use Intellia’s ex vivo CRISPR/Cas9-based allogeneic platform for the development of KYV-201 to treat autoimmune diseases & will be responsible to fund preclinical/clinical development for KYV-201 (CD19 CAR T-cell)  
• In return, Intellia received an equity stake & additional investment in Kyverna & is eligible to receive development & commercial milestone along with royalties on sales. Kyverna retains all rights outside of the US
• Intellia will receive an option to co-develop and co-promote in the US along with an opt-in fee & is eligible to share 50% development costs of KYV-201 in the US

Ref: Intellia | Image: Fierce Pharma